Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NLS Pharma Pins Hopes On Ex-Obesity Drug For ADHD

Executive Summary

Emerging Company Profile: NLS Pharma wants to develop novel treatments for ADHD, sleep disorders and cognitive impairments. Its big hope is mazindol CR, for which it has just announced promising Phase II data. The firm explains what is next.

You may also be interested in...



Sunovion's Dasotraline To Be Filed In US For ADHD Despite Uncertainties

Sunovion is pressing ahead with plans for an FDA filing for its ADHD drug dasotraline in adult and children patients despite ongoing uncertainty over the drug's efficacy in the older grouping.

COVID-19 IP Waiver 'Breakthrough' At WTO Meeting

Health advocates hail the move but the EU and UK still insist a waiver is not the solution to boosting the availability of coronavirus vaccines.

Tech Transfer Deals See Argentina And Serbia Produce COVID Vaccine

The Russian Direct Investment Fund says it has 20 technology transfer and production agreements in place in 13 countries across the world.

Topics

Related Companies

UsernamePublicRestriction

Register

SC098832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel